Cargando…

Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease

Markers of downstream events are a key component of clinical trials of disease-modifying therapies for Alzheimer’s disease. Morphological metrics like cortical thickness are established measures of atrophy but are not sensitive enough to detect amyloid-beta (Aβ)- related changes that occur before ov...

Descripción completa

Detalles Bibliográficos
Autores principales: Spotorno, Nicola, Strandberg, Olof, Vis, Geraline, Stomrud, Erik, Nilsson, Markus, Hansson, Oskar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115177/
https://www.ncbi.nlm.nih.gov/pubmed/36130332
http://dx.doi.org/10.1093/brain/awac343
_version_ 1785028152718786560
author Spotorno, Nicola
Strandberg, Olof
Vis, Geraline
Stomrud, Erik
Nilsson, Markus
Hansson, Oskar
author_facet Spotorno, Nicola
Strandberg, Olof
Vis, Geraline
Stomrud, Erik
Nilsson, Markus
Hansson, Oskar
author_sort Spotorno, Nicola
collection PubMed
description Markers of downstream events are a key component of clinical trials of disease-modifying therapies for Alzheimer’s disease. Morphological metrics like cortical thickness are established measures of atrophy but are not sensitive enough to detect amyloid-beta (Aβ)- related changes that occur before overt atrophy become visible. We aimed to investigate to what extent diffusion MRI can provide sensitive markers of cortical microstructural changes and to test their associations with multiple aspects of the Alzheimer’s disease pathological cascade, including both Aβ and tau accumulation, astrocytic activation and cognitive deficits. We applied the mean apparent diffusion propagator model to diffusion MRI data from 492 cognitively unimpaired elderly and patients with mild cognitive impairment from the Swedish BioFINDER-2 cohort. Participants were stratified in Aβ-negative/tau-negative, Aβ-positive/tau-negative and Aβ-positive/tau-positive based on Aβ- and tau-PET uptake. Cortical regional values of diffusion MRI metrics and cortical thickness were compared across groups. Associations between regional values of diffusion MRI metrics and both Aβ- and tau-PET uptake were also investigated along with the association with plasma level of glial fibrillary acidic protein (GFAP), a marker of astrocyte activation (available in 292 participants). Mean squared displacement revealed widespread microstructural differences already between Aβ-negative/tau-negative and Aβ-positive/tau-negative participants with a spatial distribution that closely resembled the pattern of Aβ accumulation. In contrast, differences in cortical thickness were clearly more limited. Mean squared displacement was also correlated with both Aβ- and tau-PET uptake even independently from one another and from cortical thickness. Further, the same metric exhibited significantly stronger correlations with PET uptake than cortical thickness (P < 0.05). Mean squared displacement was also positively correlated with GFAP with a pattern that resembles Aβ accumulation, and GFAP partially mediated the association between Aβ accumulation and mean squared displacement. Further, impairments in executive functions were significantly more associated with mean squared displacement values extracted from a meta-region of interest encompassing regions accumulating Aβ early in the disease process, than with cortical thickness (P < 0.05). Similarly, impairments in memory functions were significantly more associated with mean squared displacement values extracted from a temporal meta-region of interest than with cortical thickness (P < 0.05). Metrics of cortical microstructural alteration derived from diffusion MRI are highly sensitive to multiple aspects of the Alzheimer’s disease pathological cascade. Of particular interest is the link with both Aβ-PET and GFAP, suggesting diffusion MRI might reflects microstructural changes related to the astrocytic response to Aβ aggregation. Therefore, metrics of cortical diffusion might be important outcome measures in anti-Aβ treatments clinical trials for detecting drug-induced changes in cortical microstructure.
format Online
Article
Text
id pubmed-10115177
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-101151772023-04-20 Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease Spotorno, Nicola Strandberg, Olof Vis, Geraline Stomrud, Erik Nilsson, Markus Hansson, Oskar Brain Original Article Markers of downstream events are a key component of clinical trials of disease-modifying therapies for Alzheimer’s disease. Morphological metrics like cortical thickness are established measures of atrophy but are not sensitive enough to detect amyloid-beta (Aβ)- related changes that occur before overt atrophy become visible. We aimed to investigate to what extent diffusion MRI can provide sensitive markers of cortical microstructural changes and to test their associations with multiple aspects of the Alzheimer’s disease pathological cascade, including both Aβ and tau accumulation, astrocytic activation and cognitive deficits. We applied the mean apparent diffusion propagator model to diffusion MRI data from 492 cognitively unimpaired elderly and patients with mild cognitive impairment from the Swedish BioFINDER-2 cohort. Participants were stratified in Aβ-negative/tau-negative, Aβ-positive/tau-negative and Aβ-positive/tau-positive based on Aβ- and tau-PET uptake. Cortical regional values of diffusion MRI metrics and cortical thickness were compared across groups. Associations between regional values of diffusion MRI metrics and both Aβ- and tau-PET uptake were also investigated along with the association with plasma level of glial fibrillary acidic protein (GFAP), a marker of astrocyte activation (available in 292 participants). Mean squared displacement revealed widespread microstructural differences already between Aβ-negative/tau-negative and Aβ-positive/tau-negative participants with a spatial distribution that closely resembled the pattern of Aβ accumulation. In contrast, differences in cortical thickness were clearly more limited. Mean squared displacement was also correlated with both Aβ- and tau-PET uptake even independently from one another and from cortical thickness. Further, the same metric exhibited significantly stronger correlations with PET uptake than cortical thickness (P < 0.05). Mean squared displacement was also positively correlated with GFAP with a pattern that resembles Aβ accumulation, and GFAP partially mediated the association between Aβ accumulation and mean squared displacement. Further, impairments in executive functions were significantly more associated with mean squared displacement values extracted from a meta-region of interest encompassing regions accumulating Aβ early in the disease process, than with cortical thickness (P < 0.05). Similarly, impairments in memory functions were significantly more associated with mean squared displacement values extracted from a temporal meta-region of interest than with cortical thickness (P < 0.05). Metrics of cortical microstructural alteration derived from diffusion MRI are highly sensitive to multiple aspects of the Alzheimer’s disease pathological cascade. Of particular interest is the link with both Aβ-PET and GFAP, suggesting diffusion MRI might reflects microstructural changes related to the astrocytic response to Aβ aggregation. Therefore, metrics of cortical diffusion might be important outcome measures in anti-Aβ treatments clinical trials for detecting drug-induced changes in cortical microstructure. Oxford University Press 2022-09-21 /pmc/articles/PMC10115177/ /pubmed/36130332 http://dx.doi.org/10.1093/brain/awac343 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Article
Spotorno, Nicola
Strandberg, Olof
Vis, Geraline
Stomrud, Erik
Nilsson, Markus
Hansson, Oskar
Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease
title Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease
title_full Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease
title_fullStr Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease
title_full_unstemmed Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease
title_short Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease
title_sort measures of cortical microstructure are linked to amyloid pathology in alzheimer’s disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115177/
https://www.ncbi.nlm.nih.gov/pubmed/36130332
http://dx.doi.org/10.1093/brain/awac343
work_keys_str_mv AT spotornonicola measuresofcorticalmicrostructurearelinkedtoamyloidpathologyinalzheimersdisease
AT strandbergolof measuresofcorticalmicrostructurearelinkedtoamyloidpathologyinalzheimersdisease
AT visgeraline measuresofcorticalmicrostructurearelinkedtoamyloidpathologyinalzheimersdisease
AT stomruderik measuresofcorticalmicrostructurearelinkedtoamyloidpathologyinalzheimersdisease
AT nilssonmarkus measuresofcorticalmicrostructurearelinkedtoamyloidpathologyinalzheimersdisease
AT hanssonoskar measuresofcorticalmicrostructurearelinkedtoamyloidpathologyinalzheimersdisease